Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma
暂无分享,去创建一个
Jochen Wilhelm | Andreas Weigert | W. Seeger | S. Pullamsetti | A. Tretyn | R. Savai | F. Grimminger | T. Stiewe | L. Fink | J. Wilhelm | Thorsten Stiewe | Werner Seeger | Friedrich Grimminger | G. Banat | Rajkumar Savai | Soni Savai Pullamsetti | Ludger Fink | G-Andre Banat | Aleksandra Tretyn | Catherine Olesch | Katharina Ebel | A. Weigert | Catherine Olesch | K. Ebel | Aleksandra Tretyn
[1] S. Lebecque,et al. Dendritic Cells Infiltrating Human Non-Small Cell Lung Cancer Are Blocked at Immature Stage1 , 2007, The Journal of Immunology.
[2] Melissa H Wong,et al. Tumor microenvironment complexity: emerging roles in cancer therapy. , 2012, Cancer research.
[3] Michael R Hamblin,et al. CA : A Cancer Journal for Clinicians , 2011 .
[4] Yi-Chen Lin,et al. Tumor-associated macrophages: the double-edged sword in cancer progression. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. H. Schuenemeyer,et al. Generalized Linear Models (2nd ed.) , 1992 .
[6] F. Oesch,et al. Oncogene overexpression in non-small-cell lung cancer tissue prevalence and clinicopathological significance , 2004, Journal of Molecular Medicine.
[7] C. Powell,et al. Molecular Biology of Lung Cancer Diagnosis and Management of Lung Cancer , 3 rd ed : American College of Chest Physicians , 2013 .
[8] E. Mulvey,et al. Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. , 1995, Psychological bulletin.
[9] L. Coussens,et al. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.
[10] David A. Hume,et al. Macrophages as APC and the Dendritic Cell Myth , 2008, The Journal of Immunology.
[11] K. Calame,et al. Regulation of plasma-cell development , 2005, Nature Reviews Immunology.
[12] W. Seeger,et al. Tumor–stromal interactions in lung cancer: novel candidate targets for therapeutic intervention , 2012, Expert opinion on investigational drugs.
[13] L. Gleaves,et al. A Critical Role for Macrophages in Promotion of Urethane-Induced Lung Carcinogenesis , 2011, The Journal of Immunology.
[14] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[15] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[16] M. Merad,et al. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. , 2015, American journal of respiratory and critical care medicine.
[17] L. Zitvogel,et al. Lung cancer: potential targets for immunotherapy. , 2013, The Lancet. Respiratory medicine.
[18] A. Gemma,et al. Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer , 2008, Cancer.
[19] Z. Trajanoski,et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.
[20] J. Luketich,et al. Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. , 2011, The Journal of surgical research.
[21] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[22] C. Powell,et al. Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.
[23] W. Seeger,et al. Macrophage and cancer cell cross-talk via CCR2 and CX3CR1 is a fundamental mechanism driving lung cancer. , 2015, American journal of respiratory and critical care medicine.
[24] K. O'Byrne,et al. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Alberto Mantovani,et al. Macrophage plasticity and polarization: in vivo veritas. , 2012, The Journal of clinical investigation.
[26] Douglas Hanahan,et al. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .
[27] V. Boussiotis,et al. Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation , 2012, Science Signaling.
[28] P. McCullagh,et al. Generalized Linear Models, 2nd Edn. , 1990 .
[29] Craig Murdoch,et al. The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.
[30] Chris Maloney,et al. PubMed Central , 2017 .
[31] Rafael Sirera,et al. The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[32] J. López-González,et al. Tumor-Induced CD8+ T-Cell Dysfunction in Lung Cancer Patients , 2012, Clinical & developmental immunology.
[33] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[34] K. Cibulskis,et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.
[35] D. Maric,et al. Tumor-infiltrating myeloid cells activate Dll4/Notch/TGF-β signaling to drive malignant progression. , 2014, Cancer research.
[36] Loise M. Francisco,et al. The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.
[37] A. Yoshizawa,et al. Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung cancer. , 2013, Human pathology.
[38] L. Holmberg,et al. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. , 2013, Cancer letters.
[40] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[41] N. Martinet,et al. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. , 2002, The Journal of laboratory and clinical medicine.
[42] A. Flahault,et al. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. , 1998, The American journal of pathology.
[43] T. Dønnem,et al. Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.
[44] E. Ruffini,et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. , 2009, The Annals of thoracic surgery.
[45] B. Dahal,et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.
[46] S. Pullamsetti,et al. Adventitial Fibroblasts Induce a Distinct Proinflammatory/Profibrotic Macrophage Phenotype in Pulmonary Hypertension , 2014, The Journal of Immunology.
[47] M. Capecchi,et al. Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension , 2014, Nature Medicine.
[48] Eric R. Ziegel,et al. Generalized Linear Models , 2002, Technometrics.